The overarching themes in the Cell Stress and Biophysical Therapies (CSBT) Program are to understand how stress response pathways influences malignant transformation of cells, and in turn, to understand the ability of malignant cells to subvert and overcome the stress they endure during growth and metastasis, processes that render them more resistant to cancer therapies.
CSBT aims to reduce stress-induced malignant events and rationally modulate stress response pathways to better treat and prevent the development of aggressive cancers while protecting normal tissues and organs. Roswell Park is the only comprehensive cancer center in the nation with a CCSG Program devoted to the study of stress, and while the concept of stress covers many areas, a unifying strength of the CSBT Program is its efforts to understand diverse stresses in the framework of common and fundamental molecular mechanisms associated with cancer progression and therapeutic response and hence survivorship. CSBT Program research is organized in two Specific Aims, each of which is aligned with the strategic plans of Roswell Park: 1) to identify and target intrinsic stress response mechanisms in malignant cells and 2) to characterize the impact of physiological, environmental, and therapeutic stressors in the tumor bearing host, both systemically and within the tumor microenvironment. CSBT works very closely with other Programs, in particular DT, to translate these findings into the clinical arena. The program is co-led by Elizabeth Repasky, PhD, a laboratory scientist with wide expertise in translational research, and Anurag Singh, MD, a Radiation Oncologist, clinician- scientist who became a CSBT Program Co-Leader in February 2018. Drs. Singh and Repasky have complementary expertise that covers a broad swath of basic, translational and clinical applications of stress biology and oncology. The inherently collaborative structure of the CSBT Program is exemplified by a longstanding Program Project Grant led by Sandra Gollnick, PhD. The Program is comprised of 19 members (with 25 peer-reviewed projects) from 8 Roswell Park departments (Pharmacology & Therapeutics, Molecular & Cellular Biology, Cell Stress Biology, Surgical Oncology, Dermatology, Pathology, Immunology and Radiation Medicine) whose NCI funding is $2.4M, total peer-reviewed $2.7M, and total funding of $4.4M (project direct costs). The CSBT Program enjoys robust basic science research enhanced by inter-and intra-programmatic, national, and international research collaborations. Since the last review, NCI funding, peer-reviewed and total research support, has increased. Of the 282 publications generated over the last funding cycle, 10% were intra-programmatic, 36% were inter- programmatic collaborations and 81% inter-institutional, with 25 published in journals with an impact factor of 10 or greater. Training and mentoring opportunities for trainees and new investigators are provided within the CSBT Program. The CSBT Program has benefited from use of Shared Resources and support from the CCSG and Roswell Park. CSBT Program research is closely linked to cancers found in our catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-42
Application #
9704597
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
42
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Li, Qiuhui; Deng, Qu; Chao, Hsueh-Ping et al. (2018) Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun 9:3600
Rossetti, Stefano; Wierzbicki, Andrzej J; Sacchi, Nicoletta (2018) Undermining ribosomal RNA transcription in both the nucleolus and mitochondrion: an offbeat approach to target MYC-driven cancer. Oncotarget 9:5016-5031
Mett, V; Komarova, E A; Greene, K et al. (2018) Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene 37:439-449
Long, Mark D; Singh, Prashant K; Russell, James R et al. (2018) The miR-96 and RAR? signaling axis governs androgen signaling and prostate cancer progression. Oncogene :
Kawaguchi, Tstutomu; Yan, Li; Qi, Qianya et al. (2018) Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer. Ann Surg Oncol 25:4037-4046
Mussell, Ashley L; Denson, Kayla E; Shen, He et al. (2018) Loss of KIBRA function activates EGFR signaling by inducing AREG. Oncotarget 9:29975-29984
Hirose, Yuki; Nagahashi, Masayuki; Katsuta, Eriko et al. (2018) Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis. Sci Rep 8:10814
Vexler, Albert; Yu, Jihnhee; Zhao, Yang et al. (2018) Expected p-values in light of an ROC curve analysis applied to optimal multiple testing procedures. Stat Methods Med Res 27:3560-3576
Samuel, Sandeep; Mukherjee, Sarbajit; Ammannagari, Nischala et al. (2018) Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study. PLoS One 13:e0198809

Showing the most recent 10 out of 1555 publications